One study revealed that when paclitaxel (PTX), the representative drug of taxanes, was loaded to M1 macrophage-derived sEVs, a high amount of PTX was delivered to tumor sites, activating the NF-kB pathway [45], which significantly enhanced the anti-tumor effects. The gene discussed is NFKB1; the disease is neoplasm.